Lynn Morris to Antibodies, Monoclonal
This is a "connection" page, showing publications Lynn Morris has written about Antibodies, Monoclonal.
Connection Strength
3,007
-
4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response. J Virol. 2008 Mar; 82(5):2367-75.
Score: 0,268
-
N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. J Virol. 2007 Oct; 81(19):10769-76.
Score: 0,260
-
Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med. 2006 Jul; 3(7):e255.
Score: 0,242
-
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial. Lancet HIV. 2023 04; 10(4):e230-e243.
Score: 0,193
-
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Rep Med. 2021 06 15; 2(6):100313.
Score: 0,170
-
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N Engl J Med. 2021 03 18; 384(11):1003-1014.
Score: 0,168
-
Engineered HIV antibody passes muster. Lancet HIV. 2019 10; 6(10):e641-e642.
Score: 0,150
-
Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial. BMJ Open. 2019 07 03; 9(7):e030283.
Score: 0,149
-
Common helical V1V2 conformations of HIV-1 Envelope expose the a4ß7 binding site on intact virions. Nat Commun. 2018 10 26; 9(1):4489.
Score: 0,142
-
Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. J Virol. 2017 10 01; 91(19).
Score: 0,131
-
Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathog. 2017 01; 13(1):e1006074.
Score: 0,125
-
Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site. J Virol. 2016 Nov 15; 90(22):10220-10235.
Score: 0,124
-
The Antibody Response against HIV-1. Cold Spring Harb Perspect Med. 2012 Jan; 2(1):a007039.
Score: 0,089
-
Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One. 2011; 6(9):e23532.
Score: 0,087
-
Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. J Virol. 2011 Aug; 85(15):7719-29.
Score: 0,085
-
Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance. J Virol. 2025 Feb 25; 99(2):e0173024.
Score: 0,055
-
Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial. BMJ Open. 2023 08 28; 13(8):e076843.
Score: 0,050
-
The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol. 2003 Apr; 77(7):4449-56.
Score: 0,048
-
Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms. Sci Rep. 2022 10 01; 12(1):16473.
Score: 0,047
-
Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies. PLoS Pathog. 2022 09; 18(9):e1010450.
Score: 0,046
-
High-Throughput B Cell Epitope Determination by Next-Generation Sequencing. Front Immunol. 2022; 13:855772.
Score: 0,045
-
Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol. 2002 Mar; 76(5):2233-44.
Score: 0,045
-
Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines. Nat Commun. 2022 02 16; 13(1):903.
Score: 0,045
-
Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. Hum Vaccin Immunother. 2022 12 31; 18(1):1908030.
Score: 0,043
-
The V2 loop of HIV gp120 delivers costimulatory signals to CD4+ T cells through Integrin a4ß7 and promotes cellular activation and infection. Proc Natl Acad Sci U S A. 2020 12 22; 117(51):32566-32573.
Score: 0,041
-
Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial. BMJ Open. 2020 11 26; 10(11):e042247.
Score: 0,041
-
Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to a4ß7. PLoS Pathog. 2018 08; 14(8):e1007278.
Score: 0,035
-
Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathog. 2016 07; 12(7):e1005742.
Score: 0,030
-
The development of CD4 binding site antibodies during HIV-1 infection. J Virol. 2012 Jul; 86(14):7588-95.
Score: 0,023
-
Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol. 2009 Feb; 83(3):1240-59.
Score: 0,018
-
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol. 2006 Mar; 80(5):2515-28.
Score: 0,015